BIOGEN PHARMACHEM INDUSTRIES LIMITED has announced its financial results for the fiscal year ended March 31, 2026. The company reported a substantial increase in revenue to ₹255.80 Lakhs, a significant rise from the previous year. Profit before tax stood at ₹95.67 Lakhs, and after tax, the net profit for the year was ₹85.95 Lakhs, marking a 250% increase compared to the prior fiscal year.
BIOGEN PHARMACHEM Reports Strong FY26 Performance
BIOGEN PHARMACHEM INDUSTRIES LIMITED has unveiled robust financial results for the fiscal year ending March 31, 2026. The company demonstrated significant growth in its top-line and bottom-line figures, signaling a successful operational period.
Revenue and Profitability Growth
During the fiscal year 2025-26, BIOGEN PHARMACHEM achieved a total revenue of ₹255.80 Lakhs, a notable increase from ₹119.77 Lakhs reported in the previous fiscal year (2024-25). This growth in revenue was accompanied by a strong performance in profitability. The company posted a profit before tax of ₹95.67 Lakhs for FY26, a substantial improvement from ₹29.27 Lakhs in FY25. The net profit after tax for the fiscal year 2025-26 was ₹85.95 Lakhs, which represents a significant jump from ₹29.27 Lakhs in the prior year. This substantial increase in net profit reflects an effective management of expenses and a positive operational outcome.
Operational Highlights
The company’s operational review indicates that total expenses for FY26 amounted to ₹160.13 Lakhs, compared to ₹149.04 Lakhs in FY25. Despite a marginal increase in expenses, the significant revenue growth led to the considerable increase in profit. Key expense components include Employee Benefit Expense (₹28.28 Lakhs in FY26 vs. ₹16.79 Lakhs in FY25) and Other Expenses (₹131.85 Lakhs in FY26 vs. ₹132.25 Lakhs in FY25). The company has also highlighted that it is engaged in the business of trading in shares and securities, with its future development depending on the commencement of its operational activities.
Share Capital and Dividend Policy
The company’s issued, subscribed, and paid-up capital saw an increase due to the allotment of 25,00,00,000 Fully Convertible Warrants into Equity Shares on a preferential basis to the Non-Promoter Group on April 15, 2025. The total equity share capital as at March 31, 2026, stood at ₹9,026.03 Lakhs. For the year under review, the directors have prudently decided not to recommend any dividend to consolidate the company’s financial position.
Corporate Governance and Future Outlook
BIOGEN PHARMACHEM INDUSTRIES LIMITED is committed to good corporate governance. The Board of Directors has identified the need to find the right opportunity to make the company operational, despite current scarcity of working capital funds. Efforts are underway to implement cost reduction measures to facilitate operational readiness. The company’s future development hinges on commencing its operational activities.
Source: BSE
